Feasibility and acceptability of high-intensity interval training and moderate-intensity continuous training in kidney transplant recipients: the PACE-KD study

Roseanne E. Billany1,2, Alice C. Smith2,3, Ganisha M. Hutchinson4, Matthew P. M. Graham-Brown1,2, Daniel G. D. Nixon2,3 and Nicolette C. Bishop5*

Abstract

Background: Kidney transplant recipients (KTRs) exhibit unique elevated inflammation, impaired immune function, and increased cardiovascular risk. Although exercise reduces cardiovascular risk, there is limited research on this population, particularly surrounding novel high-intensity interval training (HIIT). The purpose of this pilot study was to determine the feasibility and acceptability of HIIT in KTRs.

Methods: Twenty KTRs (male 14; eGFR 58±19 mL/min/1.73 m²; age 49±11 years) were randomised and completed one of three trials: HIIT A (4-, 2-, and 1-min intervals; 80–90% watts at VO2peak), HIITB (4×4 min intervals; 80–90% VO2peak) or MICT (~40 min; 50–60% VO2peak) for 24 supervised sessions on a stationary bike (approx. 3x/week over 8 weeks) and followed up for 3 months. Feasibility was assessed by recruitment, retention, and intervention acceptability and adherence.

Results: Twenty participants completed the intervention, and 8 of whom achieved the required intensity based on power output (HIIT A, 0/6 [0%]; HIITB, 3/8 [38%]; MICT, 5/6 [83%]). Participants completed 92% of the 24 sessions with 105 cancelled and rescheduled sessions and an average of 10 weeks to complete the intervention. Pre-intervention versus post-intervention VO2peak (mL/kg/min) was 24.28±4.91 versus 27.06±4.82 in HIIT A, 24.65±7.67 versus 27.48±8.23 in HIIT B, and 29.33±9.04 versus 33.05±9.90 in MICT. No adverse events were reported.

Conclusions: This is the first study to report the feasibility of HIIT in KTRs. Although participants struggled to achieve the required intensity (power), this study highlights the potential that exercise has to reduce cardiovascular risk in KTRs. HIIT and MICT performed on a cycle, with some modification, could be considered safe and feasible in KTRs. Larger scale trials are required to assess the efficacy of HIIT in KTRs and in particular identify the most appropriate intensities, recovery periods, and session duration. Some flexibility in delivery, such as incorporating home-based sessions, may need to be considered to improve recruitment and retention.

Trial registration: ISRCTN, ISRCTN17122775. Registered on 30 January 2017.

Keywords: Kidney transplantation, High-intensity interval training, Cardiovascular disease, Feasibility, Chronic kidney disease

*Correspondence: N.C.Bishop@lboro.ac.uk

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Key messages regarding the feasibility

- What uncertainties existed regarding the feasibility?

There is limited information on adverse events, acceptability, and adherence to high-intensity interval training performed by kidney transplant recipients who may benefit from this type of exercise due to increased cardiovascular disease risk.

- What are the key feasibility findings?

Although participants struggled to achieve the required exercise intensity, this study highlights the potential that exercise has to reduce cardiovascular risk in kidney transplant recipients. Importantly there were no adverse events to any of the exercise protocols and no safety concerns raised.

- What are the implications of the feasibility findings for the design of the main study?

The results of this feasibility study could inform the design, sample size, and appropriate outcome measures to enhance the success of future randomised controlled trials. The results demonstrate a need to examine different high-intensity protocols in order to find the most appropriate and achievable for this population.

Background

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality after kidney transplantation and a key factor limiting graft survival [1, 2]. Most recent data suggests that for kidney transplant recipients (KTRs), CVD and cerebrovascular disease account for 19.9% of all deaths, making it the second biggest cause of mortality behind malignancy [3]. These mortality rates do not reveal the full impact of the non-fatal cardiovascular events including acute myocardial infarction, heart failure, cardiac arrhythmias, and stroke [2] all of which limit the survival of the donated kidney and quality of life (QoL) [1].

Traditional CVD predictive modelling underestimates the risk in patients with chronic kidney disease (CKD) suggesting that kidney disease and transplantation introduce unique and exacerbating features not akin to the general population [4]. Annual CVD mortality has been reported as approximately 10 times higher in KTRs aged 25–34 in comparison to the general population of equal age [5]. It is clear that KTRs have an elevated prevalence of traditional [6] and non-traditional [7] CVD risks. Weight gain, obesity, diabetes, hypertension, and metabolic syndrome are prevalent factors in KTRs linked to mortality, graft loss, and cardiac events [6]. Many of these factors are exacerbated by immunosuppressive medications [8, 9]. Unique hemodynamic challenges (anaemia, hypertension, and volume expansion) frequently seen in KTRs can accelerate cardiomyopathy without the concurrent ischaemic heart disease often seen in the general population [2]. These haemodynamic stresses likely contribute to the vascular and systemic inflammation [10] that is paradoxically common in KTRs. Elevations in novel biomarkers of inflammation are thought to not just be indicative but also play a major role in the development of CVD [11, 12]. Dialysis duration, deceased donor transplant, cytomegalovirus infection, and acute rejection episodes have been suggested as CVD risk factors rather than solely threats to graft survival [7].

There is an association between low physical activity (PA) levels and cardiovascular risk [13, 14] and an inverse relationship between PA and all-cause and CVD mortality [15]. Empirical evidence suggests that PA has ‘anti-inflammatory’ effects [11]. Despite this, levels of PA in KTRs remain lower than in the general population [16, 17]; only 27% classify as meeting nationally recommended guidelines [18]. While supervised exercise interventions in KTRs improve cardiorespiratory fitness and a variety of traditional and non-traditional risk factors for CVD, including metabolic profile [19, 20], vascular stiffening [19], weight [21], and inflammation [22], the impact of exercise programmes on hard outcomes in the long term, as well as the best exercise modalities (intensity, duration, and frequency) remain to be adequately addressed [23].

Exercise interventions in KTRs have, to date, focussed on moderate-intensity continuous training (MICT) [24]. Recently, high-intensity interval training (HIIT) programmes have received attention in both the scientific literature and the popular press for providing a unique physiological stimulus that improves traditional and inflammatory markers of cardiovascular risk in both non-clinical and clinical populations to a similar or greater degree than MICT [25], as well as being perceived as more enjoyable [26] and time efficient. Although definitions vary, HIIT is characterised by short bursts of vigorous exercise (≥80% maximal aerobic capacity or 85–95% of peak heart rate (HRpeak)) interspersed with periods of moderate-intensity exercise or rest. In CKD, HIIT has been associated with improved physical function, inflammation, and QoL in patients receiving peritoneal dialysis [27] and improved cardiorespiratory fitness in patients receiving haemodialysis [28]. It is safe, effective, and well tolerated in patients with CVD and heart transplant recipients [29–31].
Despite the potential benefits of HIIT in KTRs, patients’ views suggest that the strenuous nature may be a barrier to participation [32]. Patient and public involvement by our group has identified that KTRs, particularly those who are active, have expressed interest in HIIT but do not know whether it is safe and do not know how far they can or should “push themselves.” Therefore, the primary aim of this pilot study was to determine the feasibility and acceptability of HIIT in KTRs and the feasibility of progressing to large and complex randomised controlled trials with primary outcomes focussing on reducing cardiovascular risk in this unique population.

Materials and methods
Experimental design and participants
A full description of the trial protocol has been published [33]. This report adheres to the CONSORT guidelines for reporting pilot and feasibility trials. The PACE-KD trial was a randomised, three-arm parallel-group study to determine the feasibility and acceptability of three different supervised aerobic exercise programmes. Participants were randomised 1:1:1 to receive 24 sessions of one of two HIIT protocols or MICT across approximately 8 weeks. All groups received usual care alongside the intervention. Inclusion criteria were kidney transplant recipients >18 years old with a stable transplant completed >12 weeks prior to consent. Exclusion criteria were scheduled surgery or procedures involving anaesthesia, pregnancy, significant disease, or disorder which may put the patient at risk while taking part in the study or may influence the results of the study, and the inability to give informed consent or comply with the testing and training protocol.

Study assessments were conducted at baseline, mid-training, post-training, and 3 months post-training. Participants were recruited from the University Hospitals of Leicester NHS Trust (UHL; UK) between March 2017 and May 2019, where outcome assessments and exercise training were also conducted.

Ethical and regulatory details
The University Hospitals of Leicester NHS Trust agreed to act as sponsor for this study on October 31, 2016 (EDGE 88714). East Midlands-Nottingham Research Ethics Committee (REC; ref 16/EM/0482) gave favourable opinion on January 04, 2017. Health Research Authority regulatory approval was given on January 27, 2017, and the study was adopted on the NIHR portfolio on 12/01/2017. The trial was prospectively registered (ISRCTN17122775; January 31, 2017). Local governance approval was granted by UHL Research and Innovation on March 02, 2017. Steps were taken when designing this protocol to minimise the ethical implications and ensure patient welfare. The study complied with the International Conference for Harmonisation of Good Clinical Practice guidelines, the Research Governance Framework for Health and Social Care and was carried out in accordance with the Declaration of Helsinki.

Randomisation
Following baseline assessments, participants were randomised 1:1:1 to one of the three study groups using computer-generated random numbers (in fixed sized blocks; http://www.randomization.com) stratified by age (≤ 44 or ≥ 45) and estimated glomerular filtration rate (eGFR; ≤ 54 or ≥ 55). The Chief Investigator managed the randomisation and block sizes and allocation sequences were not disclosed.

Interventions
Participants were invited to attend 24 supervised training sessions over approximately 8 weeks on a stationary cycle ergometer. Each training session was preceded and followed by a 5-min warm-up and 10-min cool-down, respectively. Sessions were supervised by appropriately trained staff, and the heart rate was monitored throughout and guided by the baseline cardiopulmonary exercise results. Details for the intensity and time of each intervention were as follows:

HIIT A (Fig. 1A)
Each session consisted of a 16-min interval training with intervals of 4-, 2-, and 1-min duration at 80%, progressing to 90%, of watts at oxygen uptake peak (VO₂peak) over the 8 weeks, separated by a 2 min active rest (~60% VO₂peak) giving a total exercise time of 30 min.

HIIT B (Fig. 1B)
Each session consisted of 4×4 min interval training at 80%, progressing to 90%, VO₂peak, over 8 weeks, separated by a 3-min active rest, and final 5-min active stage (both ~60% VO₂peak) to ensure equal overall work done and total session time between both HIIT protocols.

MICT
Each session consisted of continuous brisk cycling for ~40 min at 50–60% VO₂peak (rating of perceived exertion (RPE) of 12–14 or ‘somewhat hard’). Time was adjusted in accordance with intensity in order to closely match MICT total external work done with both HIIT protocols.

Secondary to watts achieved, the percentage of HRpeak (based on the maximal exercise test) was used to monitor training intensity with the aim of achieving 85–95%
of HR_{peak} during the high-intensity bouts and 60% during recovery and for MICT.

**Feasibility and acceptability outcomes**

The criterion for success of this feasibility study is based on recruitment, retention, and intervention adherence and acceptability. We revised our previously reported [33] progression criteria in favour of a more pragmatic approach. Specific criteria for progressing to a larger efficacy trial were co-produced between researchers, clinicians, and patients (Table 1) using a condensed version of a previously reported method prior to completion of the study [34]. In short, any value below the specified ‘stop’ criteria and any value above the specified ‘go’ criteria are considered not feasible and feasible to progress to a larger trial, respectively. Any value between ‘stop’ and ‘go’ are considered feasible with modification.

**Secondary outcomes**

The following outcome measures were assessed in all participants at baseline and post-training: cardiorespiratory fitness (via a standard incremental protocol on a stationary cycle ergometer), body composition (via bioelectrical impedance analysis), haemodynamic parameters (via non-invasive cardiac output monitor), physical function (via sit-to-stand, 4-m gait speed, and calf strength), habitual physical activity (via accelerometry), markers of cardiovascular risk, inflammation, and immune function (data to be published elsewhere). Measures were also assessed at mid-training and 3 months post-training with the exception of cardiorespiratory fitness and habitual physical activity. A survey pack containing eight questionnaires was administered at each time point [33].

Participants who completed the intervention were invited to attend a one-to-one semi-structured interview to explore individual perspectives and feelings about the intervention and the trial design (data to be published elsewhere). A participant satisfaction questionnaire (PSQ) was also administered post-training.

A small subset of participants (n=15) were invited to receive a multiparametric cardiac MRI (CMR) scan before and after the intervention using previously reported methodology [35–38]. Ten participants consented to take part and seven completed both pre- and post-intervention scans. Data from these participants are combined for the purpose of this report.

**Data analysis**

In accordance with guidance on feasibility and pilot studies, no formal hypothesis testing has been undertaken [39]; therefore, quantitative data are summarised using descriptive statistics. Data from paper case report forms were inputted into Microsoft® Excel® then imported into

### Table 1 Progression criteria for PACE-KD

| Criteria                                                                 | Stop  | Go    | PACE-KD result |
|-------------------------------------------------------------------------|-------|-------|-----------------|
| The number of patients able to take part (eligibility)                 | <20%  | >50%  | 60%             |
| The number of patients who are eligible that agree to take part (recruitment) | <20%  | >50%  | 23%\(^a\)       |
| Whether participants achieved\(^a\) the required exercise intensity during the intervention (intervention acceptability) | <70%  | >80%  | 40%\(^b\)       |
| The number of sessions (out of 24) that participants attended (intervention completion) | <50%  | >80%  | 92%             |
| The numbers of patients who completed all aspects of the trial (trial completion/retention) | <50%  | >70%  | 58%\(^a\)       |
| Whether participants could complete the outcome measures (outcome acceptability; % for completion of one single outcome measure; example VO_{peak} | <60%  | >80%  | 95%             |

\(^a\) Values between ‘stop’ and ‘go’ can be modified to increase success

\(^b\) 75% for secondary HR_{peak} criteria
IBM® Statistical Package for Social Sciences 25 (SPSS®) for descriptive analysis and are presented as mean ± SD unless otherwise stated. No formal sample size calculation was performed as the study was pragmatic and not designed to show statistical significance or power. Data collected will allow sample size calculations to be performed for future randomised controlled trials.

Results
Recruitment and allocation
Participants were recruited between March 2017 and May 2019. The trial was stopped at the end of the grant funding with the minimum recruitment target being achieved. There are approximately 400–420 KTRs registered at University Hospitals of Leicester NHS Trust. Of the 185 patients who were assessed for eligibility, 111 were eligible, 26 were consented, and 24 were randomised (Fig. 2). The most common reasons for declining to participate (n = 85) were uncontactable following 48 h consideration period (n = 45), not interested in participating (n = 19), and the time commitment was too great (n = 9). Eight participants were allocated to each intervention.

Baseline characteristics
Baseline characteristics are shown in Table 2. Over half of participants (67%) were male, of white ethnicity (75%), and had a mean age of 48 ± 13 years. A lower proportion of males were seen in HIIT A (38%) compared to HIIT B (75%) and MICT (88%). Median transplant vintage (months) was lowest in HIIT A compared to HIITB and MICT (12 ± 20 vs. 44 ± 66 vs. 44 ± 35). Weight and VO_{2peak} were highest in MICT (86.5 ± 15.5 kg and 27.5 ± 8.73 mL/kg^{-1}/min^{-1}, respectively) compared to HIIT A (68.5 ± 15.6 kg and 23.69 ± 6.29 mL/kg^{-1}/min^{-1}), and HIIT B (84.1 ± 24 kg and 24.65 ± 7.67 mL/kg^{-1}/min^{-1}).

Trial retention and outcome measure completion
Two participants formally withdrew from the trial due to work and time commitments. Two participants were lost to follow-up during the intervention. All 20 participants who completed the intervention attended the post-training assessments. At 3 months post-training, five participants were lost to follow-up (Table 1; 58% trial completion).

For participants who attended assessment sessions the main outcome measure completion was: 98% cardiorespiratory fitness, 95% combined physical function measures, 79% survey packs, and 98% blood sampling.

Exercise adherence and acceptability
Of the 20 participants who completed the intervention, eight achieved the required exercise intensity in watts (breakdown by group: HIIT A = 0/6 [0%], HIIT B = 3/8 [38%], and MICT = 5/6 [83%]). The mean number of sessions to meet the required intensity was 13 ± 6 sessions. Detailed intensity data is shown in Table 3. Average percentage of HR_{peak} for all three groups during sessions was between 80 and 90%. Fifteen participants met the secondary HR_{peak} criteria for each session (breakdown by group: HIIT A = 4/6 [67%], HIIT B = 5/8 [63%], and MICT = 6/6 [100%]). Participants who completed the intervention attended 92% of sessions (22/24). The mean number of weeks to complete 24 sessions was 10 ± 3. There were 105 cancelled and rescheduled sessions; 68/105 for illness, 33/105 for commitments, and 4/105 for investigator illness. The main illness symptoms reported by participants throughout the intervention were cold/flu related (e.g., sneezing, headache, coughing). Numbers of days during the intervention where cold/flu symptoms were reported were: HIIT A = 14, HIIT B = 7, and MICT = 22. There were no major adverse events reported during the trial. One participant stopped exercising during a session due to pain in the abdominal area which was clinically reviewed and considered unrelated to the exercise. Another participant stopped due to pain caused by a urinary tract infection which was being treated clinically at the time.

Patient feedback
Detailed results of the PSQs can be found in Additional file 2. In summary, participants across all groups were highly satisfied with the exercise programme. There were some concerns across all groups around ability to complete the exercise required and supervision was deemed an important factor for feelings of confidence. Participants across all groups found the exercise enjoyable and beneficial and wanted to carry on exercising after the programme. Key benefits expressed by participants were improved fitness, confidence in ability to exercise, having more energy, and a motivation to continue exercising. Assessments were considered acceptable, with the exception of the survey pack, which some participants felt was too long.

Physiological measures and survey data
Summary data for physiological measurements are presented in Table 4. Survey data are presented in Additional file 1. Pre-intervention versus post-intervention VO_{2peak} (mL/kg^{-1}/min^{-1}) was 24.28±4.91 versus 27.06±4.82 in HIITA, 24.65±7.67 versus 27.48±8.23 in HIITB, and 29.33±9.04 versus 33.05±9.90 in MICT. Pre-intervention peak power output (PPO) for HIIT A was 119±22 W for HIIT A, 148±67 W for HIIT B, and 176±34 W for MICT. Post-intervention PPO were 140±22 W, 181±80 W, and 206±39 W for HIIT A, HIIT B, and MICT, respectively.
Cardiac MRI (sub-study results)

Seven of the 10 participants invited for a CMR scan completed both pre- and post-intervention scans (5 males; age 47±8 years; eGFR 53±15 mL/min/1.73m²; VO₂peak 26.88±5.67 mL/kg⁻¹/min⁻¹; PPO 179±45 W). Data are presented in Table 5.

Discussion

To our knowledge, this is the first randomised controlled trial to evaluate the feasibility and acceptability of HIIT in the kidney transplant population. To date, studies in KTRs have focused on low to moderate-intensity exercise [24, 40]. There were no reported exercise-related adverse events in any group and feedback was generally positive.
Three of our predefined progression criteria were ‘go’ (eligibility, intervention completion in terms of session attendance, and outcome completion). Two criteria, recruitment and trial completion, were acceptable (with modification) at between ‘stop’ and ‘go’. For patients who were eligible and gave reasons for not wishing to take part, time commitment was the top reason. Future trials may consider reducing the number of supervised days in favour of home-based training or a gradual decline in supervision over time but with consideration to feedback which suggests that supervision was an important contributor to participant confidence. Five participants who completed the intervention did not attend the 3-month follow-up visit which contributed to the lower trial retention figure. This may be mitigated by maintaining contact with participants post-training or providing some continuation of training in a less supervised capacity.

Overall, only 40% of participants achieved the required intensity during the intervention, taking just over half of the intervention duration to achieve this (in HIIT and MICT), suggesting a familiarisation period and longer intervention may be beneficial. More participants in the MICT group achieved their required intensity than in either HIIT group; however, they presented with a

### Table 2 Baseline characteristics

| Variable                          | All (N=24) | HIIT A (n=8) | HIIT B (n=8) | MICT (n=8) |
|-----------------------------------|------------|--------------|--------------|------------|
| Age (years)                       | 48 ± 13    | 41 ± 14      | 51 ± 11      | 52 ± 11    |
| Sex (male)                        | 16 (67)    | 3 (38)       | 6 (75)       | 7 (88)     |
| Ethnicity                         |            |              |              |            |
| White                             | 18 (75)    | 5 (63)       | 5 (63)       | 8 (100)    |
| Indian                            | 3 (13)     | 2 (25)       | 1 (13)       | 0 (0)      |
| White-Black Caribbean             | 1 (4)      | 0 (0)        | 1 (13)       | 0 (0)      |
| African                           | 1 (4)      | 0 (0)        | 1 (13)       | 0 (0)      |
| Pakistani                         | 1 (4)      | 1 (13)       | 0 (0)        | 0 (0)      |
| Body mass (kg)                    | 79.7 ± 19.7| 68.5 ± 15.6  | 84.1 ± 24    | 86.5 ± 15.5|
| BMI                               | 27.2 ± 5.6 | 25.9 ± 5.4   | 28.5 ± 7.1   | 27.1 ± 4.3 |
| V̇O₂ peak (L/min)                 | 1.99 ± 0.70| 1.56 ± 0.30  | 2.09 ± 0.86  | 2.33 ± 0.65|
| V̇O₂ peak (mL/kg⁻¹/min⁻¹)         | 25.28 ± 7.48| 23.69 ± 6.29 | 24.65 ± 7.67 | 27.5 ± 8.73|
| Systolic blood pressure (mmHg)    | 133 ± 14   | 127 ± 11     | 135 ± 17     | 137 ± 13   |
| Diastolic blood pressure (mmHg)   | 85 ± 9     | 86 ± 6       | 81 ± 6       | 88 ± 11    |
| eGFR (mL/min/1.73 m²)             | 58 ± 19    | 62 ± 18      | 57 ± 22      | 55 ± 19    |
| Serum creatinine (mmol/L)         | 125 ± 49   | 104 ± 27     | 133 ± 60     | 138 ± 53   |
| Kidney transplant vintage (months) | 35 ± 52   | 12 ± 20      | 44 ± 86      | 44 ± 35    |
| Medication                        |            |              |              |            |
| CNI                               | 24 (100)   | 8 (100)      | 8 (100)      | 8 (100)    |
| Steroid                           | 11 (46)    | 6 (75)       | 2 (25)       | 3 (38)     |
| Antihypertensive                  | 22 (92)    | 7 (88)       | 7 (88)       | 8 (100)    |
| Diabetes                          | 5 (21)     | 1 (13)       | 3 (38)       | 1 (13)     |
| Statins                           | 15 (63)    | 4 (50)       | 5 (63)       | 6 (75)     |

*Abbreviations: CNI calcineurin inhibitor, eGFR estimated glomerular filtration rate, HIIT high-intensity interval training, MICT moderate-intensity continuous training
Notes: Unless otherwise indicated, values for categorical variables are expressed as integer (% of n); values for continuous variables as mean ± SD.*median (IQR)

### Table 3 Exercise intensity data

| Variable     | HIIT A (n=6) | HIIT B (n=8) | MICT (n=6) |
|--------------|--------------|--------------|------------|
|              | High intensity | Active rest | Overall | High intensity | Active rest | Overall |
| %W_peak (All sessions) | 62 ± 7     | 44 ± 9       | 54 ± 7   | 72 ± 10     | 53 ± 10     | 64 ± 9   |
| %W_peak (Sessions 1-12) | 58 ± 7     | 44 ± 9       | 51 ± 8   | 68 ± 11     | 51 ± 9      | 60 ± 10  |
| %W_peak (Sessions 13-24) | 66 ± 6     | 45 ± 9       | 56 ± 6   | 77 ± 10     | 55 ± 10     | 67 ± 9   |
| %HR_peak (All sessions) | 88 ± 5     | 88 ± 6       | 88 ± 5   | 89 ± 10     | 90 ± 11     | 90 ± 10  |

Overall, only 40% of participants achieved the required intensity during the intervention, taking just over half of the intervention duration to achieve this (in HIIT and MICT), suggesting a familiarisation period and longer intervention may be beneficial. More participants in the MICT group achieved their required intensity than in either HIIT group; however, they presented with a
| Variable                      | HIIT A         | HIIT B         | MICt            | All            |
|-------------------------------|----------------|----------------|-----------------|----------------|
| $\text{VO}_{2\text{peak}}$ (L/min) |                |                |                 |                |
| Baseline                      | 1.55±0.30      | 2.09±0.86      | 2.25±0.62       | 1.96±0.70      |
| Post-training                 | 1.72±0.29      | 2.31±0.88      | 2.53±0.69       | 2.18±0.74      |
| $\text{VO}_{2\text{peak}}$ (mL/kg⁻¹/min⁻¹) |                |                |                 |                |
| Baseline                      | 24.28±4.91     | 24.65±7.67     | 29.33±9.04      | 25.77±7.25     |
| Post-training                 | 27.06±4.82     | 27.48±8.23     | 33.05±9.90      | 28.81±7.83     |
| Peak power output (W)         |                |                |                 |                |
| Baseline                      | 119±22         | 148±67         | 176±34          | 148±51         |
| Post-training                 | 140±22         | 181±80         | 206±39          | 176±60         |
| Overall physical activity (ENMO, mg) |                |                |                 |                |
| Baseline                      | 10.44±2.47     | 13.40±4.84     | 10.72±0.75      | 11.52±3.24     |
| Post-training                 | 11.11±3.79     | 16.35±6.01     | 12.28±3.61      | 13.25±4.85     |
| MVPA (min)                    |                |                |                 |                |
| Baseline                      | 35.84±20.92    | 59.40±28.95    | 41.64±6.20      | 45.63±21.98    |
| Post-training                 | 41.02±18.14    | 77.83±37.21    | 43.82±14.36     | 54.22±29.13    |
| Body mass (kg)                |                |                |                 |                |
| Baseline                      | 61.64±9.70     | 77.60±24.60    | 74.70±7.30      | 71.51±17.54    |
| Mid-training                  | 61.90±8.55     | 78.80±25.37    | 74.98±8.93      | 72.15±18.07    |
| Post-training                 | 61.62±9.42     | 78.45±26.20    | 74.98±8.45      | 71.91±18.56    |
| 3 months post-training        | 62.16±9.68     | 79.92±27.23    | 75.53±9.36      | 72.83±19.36    |
| BMI (kg/m²)                   |                |                |                 |                |
| Baseline                      | 23.58±2.25     | 25.92±4.97     | 24.00±2.09      | 24.63±4.04     |
| Mid-training                  | 23.74±2.07     | 26.28±6.18     | 24.03±2.54      | 24.83±4.22     |
| Post-training                 | 23.64±2.31     | 26.13±6.53     | 24.00±2.44      | 24.73±4.41     |
| 3 months post-training        | 23.88±2.85     | 26.65±6.93     | 24.23±2.68      | 25.08±4.77     |
| Body fat (%)                  |                |                |                 |                |
| Baseline                      | 27.68±8.44     | 28.08±10.19    | 20.63±7.10      | 25.96±8.91     |
| Mid-training                  | 27.08±9.13     | 28.80±10.83    | 21.40±8.47      | 26.25±9.53     |
| Post-training                 | 28.52±7.73     | 29.68±11.02    | 20.30±7.30      | 26.79±9.93     |
| 3 months post-training        | 27.80±10.26    | 30.02±11.72    | 20.65±8.22      | 26.78±10.45    |
| Skeletal muscle mass (kg)     |                |                |                 |                |
| Baseline                      | 24.62±5.48     | 31.08±11.40    | 32.93±2.81      | 29.42±8.34     |
| Mid-training                  | 25.02±5.34     | 31.25±11.37    | 32.68±3.23      | 29.55±8.24     |
| Post-training                 | 24.42±5.82     | 30.58±11.33    | 33.23±2.78      | 29.23±8.41     |
| 3 months post-training        | 24.70±5.52     | 31.08±11.53    | 33.30±2.98      | 29.55±8.45     |
| Fat free mass (kg)            |                |                |                 |                |
| Baseline                      | 44.56±9.41     | 56.02±18.97    | 59.05±4.12      | 53.01±14.05    |
| Mid-training                  | 45.14±9.11     | 56.18±18.90    | 58.50±4.69      | 53.12±13.82    |
| Post-training                 | 44.14±10.02    | 55.25±18.94    | 59.38±3.92      | 52.65±14.21    |
| 3 months post-training        | 44.78±9.49     | 55.73±19.06    | 59.50±4.37      | 53.09±14.11    |
| Lean mass (kg)                |                |                |                 |                |
| Baseline                      | 42.10±8.92     | 52.72±17.89    | 55.63±4.00      | 49.95±13.23    |
| Mid-training                  | 42.66±8.75     | 52.83±17.83    | 55.08±4.59      | 50.04±13.04    |
| Post-training                 | 41.68±9.44     | 51.82±17.77    | 55.90±3.80      | 49.53±13.31    |
| 3 months post-training        | 42.30±9.06     | 52.43±18.01    | 56.05±4.22      | 50.02±13.31    |
| Fat mass (kg)                 |                |                |                 |                |
| Baseline                      | 16.94±5.29     | 21.58±10.96    | 15.75±6.48      | 18.48±8.19     |
| Mid-training                  | 16.70±5.82     | 22.62±12.17    | 16.48±7.83      | 19.01±9.22     |
| Post-training                 | 18.98±9.31     | 23.30±12.72    | 15.60±6.85      | 19.81±10.15    |
| Variable                              | HIIT A          | HIIT B          | MICT            | All             |
|---------------------------------------|-----------------|-----------------|-----------------|-----------------|
| 3 months post-training                | 17.38±7.30      | 24.18±14.58     | 16.03±7.81      | 19.74±10.89     |
| Sit-to-stand 60 (reps)                |                 |                 |                 |                 |
| Baseline                              | 35±9            | 37±7            | 29±9            | 34±9            |
| Mid-training                          | 40±3            | 41±11           | 30±14           | 38±12           |
| Post-training                         | 45±13           | 41±11           | 31±13           | 40±13           |
| 3 months post-training                | 46±16           | 43±15           | 33±11           | 42±15           |
| Sit-to-stand 5 (sec)                  |                 |                 |                 |                 |
| Baseline                              | 8.59±2.69       | 7.96±1.27       | 10.89±3.11      | 8.95±2.50       |
| Mid-training                          | 7.65±2.01       | 7.62±2.23       | 11.04±3.62      | 8.54±2.86       |
| Post-training                         | 7.25±1.97       | 6.88±1.70       | 10.69±4.33      | 8.02±2.99       |
| 3 months post-training                | 7.04±2.05       | 6.78±1.97       | 8.90±2.43       | 7.43±2.17       |
| Gait Speed (m/s)                      |                 |                 |                 |                 |
| Baseline                              | 1.14±0.10       | 1.22±0.07       | 1.12±0.03       | 1.17±0.08       |
| Mid-training                          | 1.21±0.17       | 1.29±0.18       | 1.14±0.06       | 1.24±0.16       |
| Post-training                         | 1.18±0.16       | 1.26±0.15       | 1.17±0.02       | 1.22±0.14       |
| 3 months post-training                | 1.20±0.13       | 1.28±0.11       | 1.18±0.02       | 1.23±0.11       |
| Calf strength left (kg)               |                 |                 |                 |                 |
| Baseline                              | 40.84±9.53      | 78.24±52.93     | 63.42±31.81     | 64.65±40.05     |
| Mid-training                          | 40.87±11.36     | 71.33±53.82     | 65.43±21.84     | 62.86±37.56     |
| Post-training                         | 42.87±6.05      | 75.83±57.38     | 64.67±19.42     | 66.78±21.84     |
| 3 months post-training                | 45.21±13.33     | 78.87±60.01     | 62.19±3.03      | 65.14±41.16     |
| Calf strength right (kg)              |                 |                 |                 |                 |
| Baseline                              | 39.68±11.61     | 68.93±47.86     | 55.08±22.13     | 55.03±22.13     |
| Mid-training                          | 41.36±7.20      | 74.11±51.99     | 66.24±11.05     | 63.76±36.35     |
| Post-training                         | 46.27±4.09      | 76.65±52.18     | 64.32±22.99     | 66.28±37.03     |
| 3 months post-training                | 50.58±11.53     | 72.91±54.78     | 67.86±15.61     | 65.44±37.03     |
| Resting heart rate (beats/min)        |                 |                 |                 |                 |
| Baseline                              | 77±4            | 76±4            | 83±6            | 78±5            |
| Mid-training                          | 75±8            | 68±5            | 74±7            | 72±7            |
| Post-training                         | 76±8            | 67±4            | 78±7            | 73±7            |
| 3 months post-training                | 73±6            | 72±5            | 80±4            | 74±6            |
| Systolic blood pressure (mmHg)        |                 |                 |                 |                 |
| Baseline                              | 122±12          | 131±17          | 135±12          | 129±14          |
| Mid-training                          | 123±10          | 129±22          | 128±12          | 127±15          |
| Post-training                         | 122±11          | 122±13          | 125±12          | 123±11          |
| 3 months post-training                | 125±15          | 131±20          | 125±7           | 127±15          |
| Diastolic blood pressure (mmHg)       |                 |                 |                 |                 |
| Baseline                              | 84±6            | 79±6            | 89±10           | 83±8            |
| Mid-training                          | 80±9            | 78±4            | 84±10           | 80±8            |
| Post-training                         | 80±4            | 75±6            | 81±10           | 78±7            |
| 3 months post-training                | 80±4            | 80±7            | 81±11           | 82±7            |
| Stroke volume (ml/beat)               |                 |                 |                 |                 |
| Baseline                              | 79.84±7.91      | 102.41±28.97    | 102.51±15.96    | 94.91±22.22     |
| Mid-training                          | 82.81±13.41     | 118.05±45.48    | 107.88±9.85     | 103.59±32.56    |
| Post-training                         | 83.09±13.78     | 106.18±32.87    | 106.25±3.93     | 98.50±23.89     |
| 3 months post-training                | 80.75±14.49     | 97.94±30.27     | 98.96±7.49      | 92.40±21.73     |
| Cardiac output (L/min)                |                 |                 |                 |                 |
| Baseline                              | 6.15±0.38       | 7.76±2.29       | 8.49±1.14       | 7.41±1.82       |
| Mid-training                          | 6.10±0.60       | 7.82±2.46       | 7.86±0.21       | 7.26±1.73       |
Table 4 (continued)

| Variable                                      | HIIT A          | HIIT B          | MICT           | All            |
|-----------------------------------------------|-----------------|-----------------|----------------|----------------|
| Post-training                                | 6.22±0.62       | 7.17±2.47       | 7.32±0.21      | 6.89±1.86      |
| 3 months post-training                        | 5.80±1.34       | 7.08±2.47       | 7.85±0.53      | 6.86±1.86      |
| Total peripheral resistance (dyn-s-cm²)       |                 |                 |                |                |
| Baseline                                     | 1263.33±95.53   | 1113.84±349.26  | 1018.25±231.25 | 1138.18±259.98|
| Mid-training                                  | 1296.07±199.15  | 1096.22±358.49  | 1024.67±94.46  | 1143.76±269.16|
| Post-training                                 | 1235.00±129.58  | 1130.47±592.04  | 967.25±91.56   | 1121.79±343.49|
| 3 months post-training                        | 1440.60±324.73  | 1267.70±470.79  | 981.17±146.75  | 1248.92±384.26|
| Cholesterol (mmol/l)                          |                 |                 |                |                |
| Baseline                                     | 4.24±0.36       | 4.11±0.56       | 4.48±0.97      | 4.26±0.66      |
| Post-training                                 | 4.22±0.91       | 4.19±0.81       | 4.12±0.65      | 4.12±0.65      |
| Total cholesterol/HDL Ratio                  |                 |                 |                |                |
| Baseline                                     | 3.56±1.07       | 3.20±1.11       | 3.33±0.87      | 3.27±0.95      |
| Post-training                                 | 3.10±0.75       | 3.33±1.14       | 3.25±0.88      | 3.22±0.90      |
| Triglyceride (mmol/l)                         |                 |                 |                |                |
| Baseline                                     | 1.59±0.27       | 1.03±0.17       | 2.06±1.49      | 1.49±0.91      |
| Post-training                                 | 1.38±0.43       | 1.07±0.37       | 1.71±1.25      | 1.39±0.76      |
| Creatinine (μmol/L)                           |                 |                 |                |                |
| Baseline                                     | 107.00±20.25    | 133.00±60.15    | 137.17±58.34   | 126.45±50.10   |
| Post-training                                 | 106.00±25.43    | 132.50±51.88    | 142.67±64.05   | 127.60±49.70   |
| Phosphate (mmol/l)                            |                 |                 |                |                |
| Baseline                                     | 0.87±0.21       | 1.06±0.25       | 1.09±0.24      | 1.01±0.25      |
| Post-training                                 | 0.89±0.22       | 1.09±0.20       | 1.02±0.25      | 1.01±0.23      |
| Iron (μmol/L)                                 |                 |                 |                |                |
| Baseline                                     | 17.40±5.94      | 13.13±4.39      | 17.67±6.35     | 15.68±5.62     |
| Post-training                                 | 13.00±4.85      | 13.13±4.36      | 15.83±3.71     | 13.95±4.26     |

Abbreviations: BMI body mass index, ENMO Euclidean norm minus one, HIIT high-intensity interval training, MICT moderate-intensity continuous training, MVPA moderate to vigorous physical activity, HDL high density lipoprotein

Data are presented as mean ± SD

Table 5 Cardiac MRI and cardiorespiratory fitness sub-study data

| Variable                                      | Baseline (n=71) | Post-training (n=7) |
|-----------------------------------------------|-----------------|--------------------|
| Cardiorespiratory fitness                     |                 |                    |
| VO_{peak} (L/min)                             | 2.26±0.68       | 2.50±0.68          |
| VO_{peak} (mL/kg⁻¹/min⁻¹)                     | 26.88±5.67      | 29.99±6.99         |
| Peak power output (W)                         | 179±45          | 207±54             |
| Cardiac MRI                                   |                 |                    |
| Global native T1 time (ms)                    | 1256.1±53.6     | 1216.9±31.7        |
| LV mass (g)                                   | 134.97±31.85    | 137.26±25.53       |
| LVEF (%)                                      | 63.8±7.9        | 64.7±7.2           |
| LVM/VEDV (g/ml)                               | 0.85±0.13       | 0.85±0.12          |
| RVEF (%)                                      | 57.5±7.2        | 55.9±9.9           |
| GLS (%)                                       | -16.2±1.9       | -15.9±2.7          |
| GCS (%)                                       | -18.7±1.9       | -18.5±3.1          |
| cPEDSR (%) (°)                                | 0.98±0.18       | 0.93±0.26          |
| iPEDSR (%) (°)                                | 0.79±0.21       | 0.82±0.27          |

Abbreviations: cPEDSR circumferential peak early diastolic strain rate, GCS global circumferential strain, GLS global longitudinal strain, iPEDSR longitudinal peak early diastolic strain rate, LVEF left ventricular ejection fraction, LV left ventricular, LVEDV left ventricular end diastolic volume

Data are presented as mean ± SD

higher baseline cardiorespiratory fitness and PPO. Previous studies in heart transplant recipients and people receiving haemodialysis utilising similar HIIT protocols have based their exercise intensity on 85–95% HR_{peak} [28, 41, 42]. Hypertension is thought to affect at least 90% of KTRs [43], with a significant amount requiring anti-hypertensive therapy including beta-blockers which influence heart rate during exercise. Therefore, we applied percentage of peak watts achieved during maximal exercise testing as a primary indicator of intensity to mitigate the potential heart rate heterogeneity. However, had we used % of HR_{peak} as the primary marker of intensity, 75% of the participants would have achieved the required commonly utilised intensity of 85–95% of HR_{peak}.

There are several speculative reasons why participants in the HIIT groups were unable to achieve the required intensity (in watts) for the higher bouts; one is that participants did not have sufficient recovery during the lower intensity bouts. Mean heart rates did not drop during the recovery periods. Furthermore, we believe that the use
of a continuous ramped protocol for the cardiopulmonary exercise test was perhaps not the most appropriate to dictate the training intensity for this kind of training. While participants were able to achieve these intensities during the test, they were not maintaining them for several minutes repeatedly as in the training protocol.

Calcineurin inhibitors and corticosteroids, which are widely prescribed in KTRs, have been associated with muscle atrophy and decreased muscular oxidative capacity [44]. Peripheral muscle force is reported to be lower in lung transplant recipients compared to those with chronic obstructive pulmonary disease [44], and immunosuppressive medications similar to those taken by KTRs are thought to be a contributing factor [45]. Mathur et al. also postulate an early onset of glycolytic metabolism, potentially explaining the impairment to higher intensity exercise. Low mitochondrial gene expression of PGC-1a, NRF-1, NRF-2, TFam, mfn2, and SOD1/2 has been reported in patients with CKD (non-dialysis) compared to healthy controls [46], which could transpire in KTRs and explain the inability to achieve the intensity required within the intervention timeframe. Participants in HIIT A were far more comfortable with increasing their intensity levels during the final 1-min higher intensity bouts as opposed to the longer 4- and 2-min bouts. Participants were also more likely to want to drop their intensity level during the 4-min bouts, suggesting that shorter more intense intervals may be more acceptable. A large number of sessions were cancelled due to illness; these were mainly cold/flu symptoms which is not surprising due to immunosuppression leaving KTRs susceptible to a broad array of viral pathogens [47]. High-intensity exercise can have an immunosuppressive effect 24 h post exercise [48]; however, reported symptoms were similar between HIIT and MICT. Participants who experienced cold/flu symptoms were reluctant to return to training at the same intensity which could have slowed overall intensity progression.

Limitations include a small sample size due to the trial feasibility nature. We are unable to detect statistical changes due to inadequate powering. However, data can be used to generate sample size calculations for future trials. There is heterogeneity in participant characteristics at baseline with respect to gender, blood pressure, cardiorespiratory fitness, and transplant vintage which may have influenced responses to training. Future trials may consider further stratification or modified inclusion/exclusion criteria. To avoid differences in length of time to complete the intervention, future studies should define a set number of weeks training as opposed to a set number of sessions.

To our knowledge, this is the first study to perform pre- and post-exercise training CMR scans in KTRs. This exploratory study did not raise any safety issues, and there were no signals for adverse effects on traditional measures of cardiovascular structure and function assessed with CMR. Native T1 is a surrogate measure of myocardial fibrosis and inflammation, which are common in patients with CKD [49]. The observed reduction in native T1 times described in this study suggests a possible reduction in levels of myocardial inflammation and fibrosis, but clearly, these results are hypothesis generating and should be further explored in future studies.

Key suggestions for future studies:

- Include a familiarisation/run-in period prior to commencing the training period
- Define a set number of weeks training as opposed to set number or sessions. Twelve weeks could provide a substantial training period and allow for days missed due to illness
- Consider refinement of inclusion criteria to address the impact of factors such as current physical activity levels and kidney transplant vintage. Participants less than one year post transplant may introduce additional considerations that accompany being a new transplant recipient
- Consider further stratification during randomisation to address heterogeneity of sample
- Consider HIIT protocols with shorter intervals as participants may struggle to maintain the required power for 4 min
- Consider less intense recovery periods between high-intensity bouts
- Shorter overall sessions may help address the time commitment barrier to recruitment and barrier to exercise in general
- Consider a stepped protocol for the maximal exercise test which matches the training type rather than a continuous ramp protocol
- Consider a hybrid protocol which incorporates some home-based sessions to help address recruitment

Conclusions

HIIT and MICT performed on a cycle, with some modification, could be considered safe and feasible in KTRs. Larger scale trials are required to assess the efficacy of HIIT in KTRs and in particular identify the most appropriate intensities, recovery periods, and session duration. Some flexibility in delivery, such as incorporating home-based sessions, may need to be considered to improve recruitment and retention. This study provides evidence that both HIIT and MICT may be useful prescriptions to reduce CVD burden in KTRs.
Received: 21 April 2021 Accepted: 6 May 2022 Published online: 21 May 2022

References
1. Chan W, Bosch JA, Jones D, et al. Obesity in kidney transplantation. J Ren Nutr. 2014;24(1):1–12.
2. Kibker BA. Cardiovascular disease in kidney transplant recipients. Popul. 2007;12:13.
3. UK Renal Registry. (2021). UK Renal Registry 23rd Annual Report - data to 31/12/2019; Bristol, UK. Retrieved from renal.org/audit-research/annual-report
4. Mansell H, Rosaasen N, Dean J, et al. Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores. Clin Transplant. 2013;27(4):E391–E99.
5. Foley RN, Parfrey PS, Samak WJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5):S112–S119.
6. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82(5):S63–11.
7. de Mattos AM, Prather J, Olaya A, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006;70(4):S75–64.
8. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients. Drugs. 2004;64(18):2047–73.
9. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4(4):S83–95.
10. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol. 2009;4(7):1246–54.
11. Gleeson M, Bishop NC, Stensel DJ, et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11(9):607–15.
12. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45(10):1563–9.
13. Kriska AM, Saremi A, Hanson RL, et al. Physical activity, obesity, and the incidence of type 2 diabetes in a high-risk population. Am J Epidemiol. 2003;158(7):669–75.
14. Pereira MA, Folsom AR, McGovern PC, et al. Physical activity and incident hypertension in black and white adults: the Atherosclerosis Risk in Communities Study. Prev Med. 1999;28(3):304–12.
15. Barends NC, Hu G, Lakka TA, et al. Low physical activity as a predictor for total and cardiovascular disease mortality in middle-aged men and women in Finland. Eur Heart J. 2004;25(24):2204–11.
16. Nielens H, Lejeune TM, Lalaoui A, et al. Increase of physical activity level after successful renal transplantation: a 5 year follow-up study. Nephrol Dial Transplant. 2001;16(1):134–40.
17. Donjte ML, de Gref MH, Kruijen WT, et al. Longitudinal measurement of physical activity following kidney transplantation. Clin Transplant. 2014;28(4):394–402.
18. Wilkinson TJ, Clarke AL, Nixon DGD, et al. Prevalence and correlates of physical activity across kidney disease stages: an observational multicentre study. Nephrol Dial Transplant. 2021;36(4):641–9.
19. O’Connor EA, Koufaki P, Mercer TH, et al. Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients - a pilot randomised controlled trial. PLoS One. 2017;12(2):e0171063.
20. Masajtis-Zagajewska A, Muras K, Nowicki M. Effects of a structured physical activity program on habitual physical activity and body composition in patients with chronic kidney disease and in kidney transplant recipients. Esp Clin Transplant. 2019;17(2):155–64.
21. Roj GS, Stofoni S, Mosconi G, et al. Physical activity in solid organ transplant recipients: organizational aspects and preliminary results of the Italian project. Transplant Proc. 2014;46(7):2345–9.
22. Romano G, Simonella R, Falletti E, et al. Physical training effects in renal transplant recipients. Clin Transplant. 2010;24(4):S10–4.
23. Calella P, Hernandez-Sanchez S, Garofalo C, et al. Exercise training in kidney transplant recipients: a systematic review. J Nephrol. 2019;32(4):567–79.

24. Oguchi H, Tsubita M, Yazawa M, et al. The efficacy of exercise training in kidney transplant recipients: a meta-analysis and systematic review. Clin Exp Nephrol. 2019;23(2):275–84.

25. Ramos JS, Dalleck LC, Tjonna AE, et al. The impact of high-intensity interval training versus moderate-intensity continuous training on vascular function: a systematic review and meta-analysis. Sports Med. 2015;45(5):679–92.

26. Bartlett JD, Close GL, MacLaren DP, et al. High-intensity interval running is perceived to be more enjoyable than moderate-intensity continuous exercise: implications for exercise adherence. J Sports Sci. 2011;29(6):547–53.

27. Rouchon MI, Coutard C, Matysiak M, et al. High intensity interval training improves physical functioning, inflammation and quality of life in post-transplant dialysis patients. Nephrol Dial Transpl. 2016;31:S8.

28. Nilsson BB, Bunaia-Naiss H, Edvardsen E, et al. High-intensity interval training in haemodialysis patients: a pilot randomised controlled trial. BMJ Open Sport Exerc Med. 2019;5(1):e000617.

29. Rognmo Ø, Hietland E, Helgerud J, et al. High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2004;11(3):216–22.

30. Dall CH, Gustafsson F, Christensen SB, et al. Effect of moderate- versus high-intensity exercise on vascular function, biomarkers and quality of life in heart transplant recipients: a randomized, crossover trial. J Heart Lung Transplant. 2015;34(8):1033–41.

31. Perrier-Melo RJ, Figueira F, Guimarães GV, et al. High-intensity interval training in heart transplant recipients: a systematic review with meta-analysis. Arq Bras Cardiol. 2018;110(2):188–94.

32. Lloyd-Davies LC, Brown S, Hull K, et al. Renal transplant recipient perspectives on physical activity and exercise. Proc Am Soc Nephrol Annu Meet. 2014;2014:370.

33. Bishop NC, Billany R, Smith AC. Participant acceptability of exercise in kidney disease (PACE-KD): a feasibility study protocol in renal transplant recipients. BMJ Open. 2017;7(9):e017494.

34. Young HML, Goodliffe S, Madhani M, et al. Co-producing progression criteria for feasibility studies: a partnership between patient contributors, clinicians and researchers. Int J Env Res Pub He. 2019;16(19):3756.

35. Graham-Brown MPM, March DS, Churchward DR, et al. Design and methods of CYCLE-HD: improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise: a randomised control trial. BMC Nephrol. 2016;17(1):69.

36. Graham-Brown MR, March DS, Churchward DR, et al. Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients. Kidney Int. 2016;90(4):835–44.

37. Graham-Brown MPM, Adenwalla SF, Lai FY, et al. The reproducibility of cardiac magnetic resonance imaging measures of aortic stiffness and their relationship to cardiac structure in prevalent haemodialysis patients. Clin Kidney J. 2018;11(6):864–73.

38. Graham-Brown MF, Gulsin GS, Parke K, et al. A comparison of the reproducibility of two cine-derived strain software programmes in disease states. Eur J Radiol. 2019;113:51–8.

39. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.

40. Orlando G, Soti F, Moscarelli L, et al. Exercise prescription in renal transplant recipients: from sports medicine toward multidisciplinary aspects: a pilot study. J Funct Morphol Kinesiol. 2020;5(1):10.

41. Nytraen K, Rustad LA, Aukrust P, et al. High-intensity interval training improves peak oxygen uptake and muscular exercise capacity in heart transplant recipients. Am J Transplant. 2012;12(1):3134–42.

42. Rustad LA, Nytraen K, Amundsen BH, et al. One year of high-intensity interval training improves exercise capacity, but not left ventricular function in stable heart transplant recipients: a randomised controlled trial. Eur J Prev Cardiol. 2012;21(2):181–91.

43. Glücklich D, Lamba R, Pawar R. Hypertension in the kidney transplant recipient: overview of pathogenesis, clinical assessment, and treatment. Cardiol Rev. 2017;25(3):102–9.

44. Mathur S, Levy RD, Reid WD. Skeletal muscle strength and endurance in recipients of lung transplants. Cardiopulm Phys Ther J. 2008;19(3):84–93.

45. Mador MJ, Bozkasat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Resp Res. 2001;2(4):216–24.

46. Watson EL, Baker LA, Wilkinson TJ, et al. Reductions in skeletal muscle mitochondrial mass are not restored following exercise training in patients with chronic kidney disease. FASEB J. 2020;34(1):1755–67.

47. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005;16(6):1758.

48. Bishop NC, Walker GJ, Bowley LA, et al. Lymphocyte responses to influenza and tetanus toxoid in vitro following intensive exercise and carbohydrate ingestion on consecutive days. J Appl Physiol. 2005;99(4):1327–35.

49. Hayer MK, Price AM, Liu B, et al. Diffuse myocardial interstitial fibrosis and dysfunction in early chronic kidney disease. Am J Cardiol. 2018;121(5):656–60.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.